Quidel (NASDAQ:QDEL) Upgraded by StockNews.com to “Buy”

Quidel (NASDAQ:QDELGet Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday.

A number of other research analysts also recently issued reports on QDEL. Raymond James upgraded shares of Quidel from an “outperform” rating to a “strong-buy” rating and dropped their target price for the company from $155.00 to $130.00 in a research report on Tuesday, February 22nd. TheStreet downgraded shares of Quidel from a “b-” rating to a “c+” rating in a research report on Thursday, February 10th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $143.50.

NASDAQ:QDEL opened at $92.49 on Friday. The firm’s fifty day moving average is $106.89 and its 200-day moving average is $118.21. Quidel has a 52 week low of $88.05 and a 52 week high of $180.06. The firm has a market cap of $3.87 billion, a P/E ratio of 3.90 and a beta of 0.02.

Quidel (NASDAQ:QDELGet Rating) last released its earnings results on Wednesday, May 4th. The company reported $11.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.17 by $2.49. Quidel had a net margin of 43.26% and a return on equity of 56.46%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $865.05 million. During the same quarter in the previous year, the company earned $4.27 EPS. Quidel’s quarterly revenue was up 167.0% compared to the same quarter last year. As a group, equities analysts expect that Quidel will post 16.34 EPS for the current year.

In other Quidel news, Director Mary Lake Ph D. Polan sold 1,525 shares of the company’s stock in a transaction on Friday, March 18th. The shares were sold at an average price of $113.59, for a total transaction of $173,224.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of QDEL. Western Pacific Wealth Management LP bought a new stake in shares of Quidel in the 4th quarter worth $26,000. New Century Advisors LLC purchased a new position in Quidel in the fourth quarter valued at about $31,000. Exane Derivatives grew its position in shares of Quidel by 4,883.3% during the 1st quarter. Exane Derivatives now owns 299 shares of the company’s stock valued at $34,000 after acquiring an additional 293 shares during the period. Emerald Advisers LLC purchased a new stake in shares of Quidel during the 4th quarter worth approximately $40,000. Finally, Vestor Capital LLC bought a new stake in shares of Quidel in the 3rd quarter worth approximately $42,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Quidel (Get Rating)

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye.

Read More

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.